Journal of Cell Science and Therapy最新文献

{"title":"Immediate Expander Implantation Following Simple Mastectomy of a Seven Kilograms Giant Phyllodes Tumor","authors":"Qiannan Zhu, T. Xia, Li-jun Ling, Jingping Shi, Shui Wang","doi":"10.4172/2157-7013.1000219","DOIUrl":"https://doi.org/10.4172/2157-7013.1000219","url":null,"abstract":"We report a case of a 45-year-old Chinese-American woman with a giant phyllodes tumor measuring 29×27×22 cm. The patient relied on traditional Chinese medicine (TCM) and physical massage for more than one year before surgery. A simple mastectomy with immediate expander implantation was performed. During the surgery, a suspicious lymph node was found which might be related to breast massage. We kept superior and inferior skin flaps to cover the skin defect and reconstruct a breast shape one-stage operation.","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":" 14","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120828859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanistic Progress of Estrogen-induced Apoptosis in Estrogen-deprivedBreast Cancer Cells","authors":"S. Chai, P. Fan","doi":"10.4172/2157-7013.1000218","DOIUrl":"https://doi.org/10.4172/2157-7013.1000218","url":null,"abstract":"The laboratory discovery of estrogen-induced apoptosis has been translated to treat antihormone resistant patients and to reduce the incidence of breast cancer in postmenopausal hysterectomized women with estrogen replacement therapy (ERT). The key step is the selection pressure exerted by long-term antiestrogen therapy or over 5 years of menopause to specific breast cancer cell populations that will be vulnerable to estrogen-induced apoptosis. However, the mechanisms underlying estrogen-induced apoptosis are currently unclear. At the cellular level, estrogen-induced apoptosis is dependent upon the estrogen receptor (ER), which can be completely blocked by antiestrogen ICI 182,780 or 4-hydroxytamoxifen (4-OHT). Knockdown of ER alpha, but not ER beta, through specific small interfering RNAs effectively blocks estrogen-induced apoptosis, indicating that the ER alpha subtype participates in apoptosis. Further examinations demonstrate that estrogen-induced apoptosis is due to accumulation of endoplasmic reticulum stress, inflammatory responses, and oxidative stress, which, in turn, activate the intrinsic mitochondrial pathway and the extrinsic death receptor pathway to complete the process. This contrasts with paclitaxel, which causes G2 arrest with immediate apoptosis. These stress responses are modulated by glucocorticoids and the c-Src inhibitor to block estrogen-induced apoptosis, but the mechanism for estrogen action is through a genomic pathway rather than a non-genomic pathway. In the nucleus, estrogen activates classic ERE-regulated endogenous genes, but the ERE transcriptional pathway does not directly participate in the estrogen-induced apoptosis in vitro or in vivo. Simultaneously, estrogen activates a non-classic transcriptional pathway involving the interaction of ER with transcription factors such as activator protein-1 (AP-1), which may regulate proliferation, stress responses, or apoptosis. Investigation of how AP-1 modulates the stress responses to trigger estrogen-induced apoptosis will ultimately uncover the mechanisms underlying estrogen-induced apoptosis.","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126173559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TSGA10 is a Centrosomal Protein, Interacts with ODF2 and Localizes to Basal Body","authors":"B. Behnam, M. Mobahat, H. Fazilaty, J. Wolfe, H. Omran","doi":"10.4172/2157-7013.1000217","DOIUrl":"https://doi.org/10.4172/2157-7013.1000217","url":null,"abstract":"TSGA10 is overexpressed in some cancers, during neural development, in embryogenesis, and in several tissues with actively dividing cells. TSGA10 protein localization to the sperm tail has been previously described. The protein is cleaved into two parts, which appear to play different functions in the sperm tail: the 27-KDa N-terminal is localized to the fibrous sheath in the principal piece, whereas its 55-KDa C-terminal of the TSGA10 forms filaments, decreases transcriptional activity of hypoxia-inducible factor (HIF)-1-alpha and accumulates in the midpiece of mature spermatozoa. Using colocalization, and coimmunoprecipitation assays, we show that TSGA10 interacts with ‘Outer Dense Fiber 2’ (ODF2), a centrosome scaffold component associated with mother centrioles. Also, our yeast two-hybrid assay shows that the full-length TSGA10 protein and its 55-KDa C-terminus portion predominantly interact with ODF2. However, the truncated N-terminus 27-KDa fibrous sheath component of TSGA10 fails to bind ODF2. Our experiments examining the localization of TSGA10, demonstrated that the full length TSGA10 protein localizes to perinuclear structures, colocalizes with γ-tubulin, and associates with the centrosome and basal body. The TSGA10 55-KDa C-terminus, but not its 27-KDa N-terminus also localizes to the centrosome and basal body. Our Real-time PCR data indicated that the levels of TSGA10 and ODF2 genes expressions correlate, in mice testes. Finally, we propose that TSGA10 is a ciliary-centrosomal protein and therefore is a good candidate for further investigation in ciliopathies, as well as, cancer biology.","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125291643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ER Intrabodies: Potent Molecules for Specific Knockdown of Proteins Passingthe ER","authors":"T. Boldicke","doi":"10.4172/2157-7013.1000214","DOIUrl":"https://doi.org/10.4172/2157-7013.1000214","url":null,"abstract":"A very promising protein knockdown technique is based on recombinant antibody fragments expressed inside the ER (ER intrabodies). ER intrabodies mediate inhibition of the function of proteins passing the ER very efficiently and specifically. Many ER intrabodies against a large range of attractive targets have been described [2,3]. Targets include oncogenic receptors, virus proteins (to prevent virus assembly), cellular virus receptors (to block virus entry), proteins of the immune system and the nervous system [4-8]. Even ER intrabodies with therapeutic potential have been generated [9-15].","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"111 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124054225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Epidemiological Survey on the Awareness towards Orthodontic Treatment among Middle School and High School Children of Karnataka State","authors":"Roopa Siddegowda","doi":"10.4172/2157-7013.1000213","DOIUrl":"https://doi.org/10.4172/2157-7013.1000213","url":null,"abstract":"Context: Malocclusion can conciliate the oral health tissues and can lead to social and psychological problem. Hence an investigation of the malocclusion status in growing children to intercept the same is required \u0000Aims: To assess the awareness towards Orthodontic treatment among middle school and high school children of Karnataka state. Settings and design: School settings and Descriptive cross-sectional survey \u0000Methods and Material: A cross-sectional epidemiological survey was conducted in all the 30 districts of Karnataka. School children in the age group of 10-16 years were the target population. Population proportionate technique was employed for the sample size estimation. A total sample of 9505 was randomly selected from 102 schools all over Karnataka. A pre-structured questionnaire was used to assess the awareness of children towards orthodontic treatment. Statistical analysis used: Simple descriptive statistics, t-test. \u0000Results: High school children exhibited high awareness with respect to the statement 5, 6, 8 and 14 when compared with the middle school children. Similarly middle school children had high awareness with respect to the statement 9, 10 and 12. Conclusions: High school children showed a higher level of awareness about orthodontic treatment when compared to middle school children.","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129638725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined Large Cell Neuroendocrine Carcinoma of the Lung","authors":"M. Kooblall, S. Crowther, E. Moloney, S. Lane","doi":"10.4172/2157-7013.1000216","DOIUrl":"https://doi.org/10.4172/2157-7013.1000216","url":null,"abstract":"We report the case of a 74 year old man, non-smoker who presented with a 3 months history of weight loss and nausea. Apart from an irregular pulse, clinical examination was normal. Blood biochemistry revealed an elevated alkaline phosphatase with hypercalcemia. CXR showed right lower lobe pleural thickening. CT Thorax/Abdomen/ Pelvis followed by a PET scan revealed 4.2 cm right lower lobe mass with FDG avid pleural, extra pleural, pancreatic and osseous lesions. Interestingly CT core biopsy of the right lower lobe showed an unusual histopathology: nonsmall cell carcinoma with acinar growth pattern consistent with adenocarcinoma and cells showing neuroendocrine features with pleomorphism CD56 positivity and chromogranin positivity in solid area. These features were suggestive of a combined large cell neuroendocrine carcinoma of the lung.","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124785636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Vivo Biocompatibility Testing of a Collagen Cell Carrier Seeded withHuman Urothelial Cells in Rats","authors":"L. Daum, S. Maurer, M. Vaegler, K. Sievert","doi":"10.4172/2157-7013.1000215","DOIUrl":"https://doi.org/10.4172/2157-7013.1000215","url":null,"abstract":"Tissue-engineered, matrix-stabilized autologous urothelium is a new option for urethral reconstruction, particularly for patients for whom other autologous grafts are not available. In vitro engineering of urothelial tissue requires biomaterials as cell carriers that increase the stability of cell-based implants. The aim of this study was to investigate a new highly standardized, industrially manufactured bovine collagen type I-based cell carrier (CCC) for its suitability as a carrier matrix for human urothelial cells (HUC). As an in vivo biocompatibility test the behaviour and degradation of these implants was to be proven in a nude rat model. Expanded HUC from tissue biopsies were phenotypically analysed by immuno¬cyto¬chemistry and seeded onto CCC. For in vivo application, CCC was seeded with PKH26-labelled HUC in high density and constructs were implanted onto the rectus abdominis muscle of nude rats. Integration, cell survival, and degradation of the urothelium-matrix-implants were studied after 1, 2, and 4 weeks. Immunohistological characterization of multilayered urothelium-matrix-constructs was performed for AE1/AE3 and p63 (epithelial phenotype), CK20 (differentiation), and E-Cadherin and ZO-1 (junction formation). Immunocytochemical staining showed urothelial character of the isolated cells and the absence of fibroblasts and muscle cells. In twelve nude rats, urothelium-matrix-implants integrated well into the host tissue where no inflammation was observed. Immuno¬fluorescence analysis confirmed epithelial phenotype, adherence and tight junction formation homogeneous multilayer formation of stratified HUC cultures as well as urothelial phenotype and differentiation in vitro the CCC-matrix additionally revealed promising biocompatibility investigated in a nude rat model. Thus, this study demonstrates excellent suitability of CCC as a matrix for urothelial cells and recommends its use in a large animal model with regard to clinical application.","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131706909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Nanovaccine in Immunotherapy","authors":"Megha Agarwal","doi":"10.4172/2157-7013.S8-003","DOIUrl":"https://doi.org/10.4172/2157-7013.S8-003","url":null,"abstract":"Nanotechnology, although not a new concept, has attained notable momentum in recent years. Due to the modern approach in material science and nano-engineering in the preceding decade, the nanoparticles have become incredibly striking for their applications in the fields of biology and medicine. There are significant applications of nanoscience in biology and biotechnology. Nanotechnology can be used to facilitate the therapy targeting immune system. The initiative that a nanostructure could be assembled, constructed and introduced into the human body to progress health, together with cellular repairs at the molecular level, is promising. The utilization of nanotechnology to medicine, known as nanomedicine, deal with the use of accurately engineered materials at this length scale to build up novel therapeutic and diagnostic modalities. Biodegradable nanoparticles are attaining amplified consideration for their capacity to serve as a feasible carrier for site specific distribution of vaccines, genes, drugs and other biomolecules in the body. They offer improved biocompatibility, superior drug/vaccine encapsulation, and expedient release profiles for several drugs, vaccines and biomolecules to be used in an array of applications in the area of medicine. The small size, customized surface, superior solubility, and multi-functionality of nanoparticles will persist to open numerous doors and generate novel biomedical applications. Certainly, the peculiar properties of nanoparticles offer the facility to interact with multifacet cellular functions in new ways. The nanomaterial is so minute that it can effortlessly enter the cell; therefore, nanomaterials can be used in vivo or in vitro for biological applications. Nanovaccine is rising as a novel path to the methodology of vaccination. Nanoparticles can also be used to cargo diverse types of cytokines like LIF and IL-6. This targeted nanoparticle approach is competent to harness endogenous immune-regulatory pathways, providing a potent new process to modulate T cell developmental plasticity in immune-mediated disease indications","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"72 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127279463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Squamous-Cell Gallbladder Carcinoma: How to Treat?","authors":"L. Verlicchi, H. Blons, L. Hannoun, J. Bachet","doi":"10.4172/2157-7013.1000212","DOIUrl":"https://doi.org/10.4172/2157-7013.1000212","url":null,"abstract":"Squamous-cell gallbladder carcinoma is a very rare cancer with very few therapeutic data available in the literature. We describe a case of this rare disease with a good response under Gemcitabine and Cisplatin after several previous lines of chemotherapy, in an 80-year-old man. In our case, the disease was resistant to FOLFOX, FOLFIRI and Paclitaxel but an impressive partial response was shown after 9 cycles of Gemcitabine and Cisplatin in fourth-line of chemotherapy. Unfortunately, a progression occurred after 12 cycles (7 months). With the intent of finding a new therapeutic option a molecular analysis was performed using Next-Generation Sequencing and two mutations of ERBB2 and PTEN were found. A standard regimen of chemotherapy for squamous-cell gallbladder cancer does not exist and, because of the rarity of this type of cancer, therapeutic trials will probably never be conducted. The end point of this works is to describe this interesting case and make a review of the literature about treatments used for squamous-cell carcinoma of the gallbladder.","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128976376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Strategy for the Treatment of Anemia","authors":"Guorui Huang","doi":"10.4172/2157-7013.S8-001","DOIUrl":"https://doi.org/10.4172/2157-7013.S8-001","url":null,"abstract":"Being the most common type of blood cell, erythrocytes are the principal means of delivering oxygen (O2) to tissues in the human body. In order to provide more space for hemoglobin, these cells lose nuclei during development as they mature. Additionally, erythrocytes lose all other cellular organelles such as their mitochondria, Golgi apparatus, and endoplasmic reticulum in mammals. Erythrocyte development lasts for around 7 days, starting as stem cells and becoming mature erythrocytes. Following development, the functional lifetime of mature erythrocytes is about 100-120 days [1].","PeriodicalId":150547,"journal":{"name":"Journal of Cell Science and Therapy","volume":"146 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132697438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}